BLINCYTO 38.5 MCG — DIN 02450283
BLINATUMOMAB : 38.5 MCG · AMGEN CANADA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is BLINCYTO?
BLINCYTO 38.5 MCG contains BLINATUMOMAB : 38.5 MCG. It is listed in the Health Canada Drug Product Database under DIN 02450283, held by AMGEN CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 17-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Blinatumomab cost around the world?
Blinatumomab is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 8 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 3 | NOK███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
23 pack listings across 14 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Blinatumomab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 38.5 MCG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Blinatumomab |
|---|---|
| ATC code | L01FX07 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02450283 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2450283 |
| Brand name | BLINCYTO |
| Generic / active ingredient | BLINATUMOMAB : 38.5 MCG |
| Market authorization holder | AMGEN CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01FX07 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01FX |
| Current status | MARKETED |
| Status date | 17-Mar-2016 |
| Original market date | 2016-03-17 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L01FX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Polatuzumab Vedotin | POLIVY | 2 | 2 | Yes |
| Teclistamab | TECVAYLI | 2 | 2 | Yes |
| Belantamab Mafodotin | BLENREP | 2 | 2 | Yes |
| Glofitamab | COLUMVI | 2 | 2 | Yes |
| Talquetamab | TALVEY | 2 | 2 | Yes |
| Tarlatamab | IMDELLTRA | 2 | 2 | Yes |
| Elranatamab | ELREXFIO | 2 | 2 | Yes |
| Enfortumab Vedotin | PADCEV | 2 | 2 | Yes |
| Epcoritamab | EPKINLY | 2 | 2 | Yes |
| Blinatumomab | BLINCYTO | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01F
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01FD | Pertuzumab · Trastuzumab · Trastuzumab Deruxtecan · Trastuzumab Emtansine | 18 | 16 |
| L01FG | Bevacizumab · Ramucirumab | 14 | 14 |
| L01FF | Atezolizumab · Avelumab · Cemiplimab · Dostarlimab · Durvalumab · +3 more | 14 | 12 |
| L01FA | Obinutuzumab · Ofatumumab · Rituximab | 11 | 8 |
| L01FC | Daratumumab · Isatuximab | 5 | 5 |
| L01FY | Nivolumab And Relatlimab · Pertuzumab And Trastuzumab | 4 | 4 |
| L01FE | Cetuximab · Necitumumab · Panitumumab | 5 | 3 |
| L01FB | Inotuzumab Ozogamicin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.